AzTrials
AzTrials

Cardiac DiseasesPEN PlusNCT07753681

Domestication and Implementation of the PEN-Plus Clinical Model in the Zambian Health System

An observational study of Cardiac Diseases and Sickle Cell Disease, run by Centre for Infectious Disease Research in Zambia at 1 site in Zambia.

Recruiting

Looking for participants now. Contact the study team or a site below to ask about taking part.

Sites and contacts
Official record
Search all trials

Trial summary

Cognizant of the prevalence of complicated non communicable diseases (NCD) and the attendant capacity problems faced by the health workers in primary care settings, we propose to adapt and pilot the Package of Essential Non-communicable Diseases (PEN) Plus intervention using the Interactive Systems Framework (ISF) and… Read more about this study

Who is it for?
Any age
What is being tested?
Supportive treatment
How many people
2,084 participants
Where
1 siteZambia
Study dates
8 Aug 2022to 30 Sep 2027
How long will I take part?
1 Month
Phase
Observational
Are there results?
Not yet: the study is under way

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages Any age
  • All sexes
  • No healthy volunteers
  • Child, Adult, Older adult

Study population: All individuals in Zambian community that live around the Intervention facilities and present with NCDs or are known NCD patients.

Who may be able to join

  • Presenting with chronic NCDs

Who cannot join

  • Refusing to be followed up prospectively for routine visits

Trial locations and contacts

1 site in 1 country. Contact the study team or a site near you to ask about taking part.

Bupe Sichalwe, ADULT EDUCATION contact

977401513 ext. +260

bupe.sichalwe@cidrz.org

Zambia1 site, 1 recruiting
  • Matero First Level Hospital

    Lusaka, Lusaka Province, 10101

    Fastone M Goma

    Recruiting

Other trials in Zambia

About this study

Official title: PEN-Plus Initiation Grant Opportunity: Domestication and Implementation of the PEN-Plus Clinical Model in the Zambian Health System

Cognizant of the prevalence of complicated non communicable diseases (NCD) and the attendant capacity problems faced by the health workers in primary care settings, we propose to adapt and pilot the Package of Essential Non-communicable Diseases (PEN) Plus intervention using the Interactive Systems Framework (ISF) and then implement and monitor the impact. The ISF framework proposes and organizes several implementation strategies to achieve Evidence Based Implementation (EBI) adaptation. We will apply these strategies at 2 first level hospitals (Peri-Urban and Rural) to ensure local adaptation and work towards scaling up of the WHO-PEN Plus in the rest of Zambia. This process will be inclusive, involving a Stakeholder Consultation Group that shall include the Zambian Non-Communicable diseases and injuries (NCDI) Poverty Commission and shall report bi-annually to a Project Advisory Board (PAB) chaired by the Permanent Secretary of the Ministry of Health.

Read the detailed description

In Zambia, NCDs are among the top 10 causes of mortality, and the current National Health Strategic Plan 2017-2021 has placed NCDs as a priority area for intervention, with the government and cooperating partners working to address this growing threat. Though population level data on NCDs is not available in Zambia, routine data collected from hospitals have shown a 22% increase in the total number of NCDs cases between 2010 and 2012 in all age groups. In the same period, cases of hypertension seen in the outpatient department (OPD) increased by 39% for all age groups. Cancer cases seen at the country's only Cancer Diseases Hospital (CDH) increased from 1282 in 2010 to 3021 in 2014, exhibiting an increase of over 50%. There is definite reason to change the interventional strategy if Zambia is to get anywhere towards attaining the WHO '25 x 25' global NCD targets, an important milestone towards the achieving the SDG No.3. To date, the rate of progress on NCDs has been patchy, uneven and largely off-track. The imperative for action is reinforced by persistent gaps and shortcomings in the response, ranging from lack of prioritization of NCDs, inadequate resources, a lack of preventative action, vulnerable and ill-equipped health systems to respond to the growing burden.

The WHO-PEN survey done in 2017 revealed gaps in primary health care capacity to manage NCDs in Zambia, with almost all health facilities failing to reach the minimum threshold. Only six (6) out of the 46 facilities surveyed were deemed ready to manage NCDs. The only first level hospital included in the survey just crossed the line. While it scored above the threshold for basic equipment, diagnostic capacity, essential medicines and essential services, it got a rather low score for counselling services. Overall urban and semi-urban facilities fared better than the rural facilities. This was a typical reflection of the Zambian health system which has remained focused on infectious rather than non-communicable diseases.

This protocol is developed for a mixed methods evaluation based on the United Kingdom's Medical Research Council (MRC) framework for complex interventions guided by the Proctor implementation frameworks. The evaluation is designed to reflect overarching research questions across all sites, but also allows for the considerable variability in implementation practices and needs across the ten countries. Here we aim to understand:

  1. Clinical implementation outcomes: Are PEN-Plus clinics enrolling sufficient numbers of patients largely with severe chronic non communicable diseases, and particularly type 1 diabetes, and are they reaching the poorest? Is the care being provided at these new clinics acceptable and comparable in quality to tertiary chronic care facilities in their country? Are patients enrolled in these clinics being protected from further impoverishment? What is the cost of providing these services? Are patients' voices being heard?
  2. Training outcomes: Over the course of the project, what is the readiness of the supported facilities to become national training centers for PEN-Plus? How many midlevel providers have been prepared to become PEN-Plus master trainers including a sufficient period of clinical practice precepted by internal medicine specialists, pediatricians, cardiologists, and endocrinologists? Is the PEN-Plus clinic space adequate for a training facility? What is the six-month retention of these midlevel providers?
  3. Policy outcomes: Has the Ministry of Health, together with its partners, begun to develop the policies and strategies needed to enable the implementation of PEN-Plus services at a national scale? These policies and strategies include: disease management guidelines, medication formularies, patient medical record forms, health management information systems, training curricula and certification pathways for providers, national PEN-Plus operational plans, and resource mobilization plans. 1.6 Objective and Aim of the study 1.6.1 General Objective The overarching objective/aim of the study is to adapt and pilot the PEN PLUS intervention using the Interactive Systems Framework (ISF) and then implement and monitor the impact. The ISF framework proposes and organizes several implementation strategies to achieve Evidence Based Implementation (EBI) adaptation, including dissemination, implementation processes, integration, capacity building and scale up strategies. We will apply these strategies at different levels to different actors to ensure local adaptation and scaleup of the WHO-PEN Plus in Zambia Aims Aim 1. Adapt WHO-PEN PLUS for screening and management of NCDs in Zambian Hospitals and health facilities - Engagement of Delivery System Actors: The following strategies shall be adopted
  • Engagement of key stakeholders;
  1. Formation of the Stakeholder Consultation Group
  2. Establishment of the baseline of service availability for NCDs
  3. Redefining the referral chain and identifying community structures
  • Adaptation of WHO-PEN PLUS to the Zambian primary service delivery setting a. Identification of priority conditions (from the Zambia NCDI Poverty Commission) b. Identification of gaps between what is available and what would be ideal for dealing with these conditions.
  1. Define Care Delivery Package (including diagnostics and treatment capacity)
  • Evaluation of the implementation processes through real-time monitoring and evaluation.
  1. Establish a localised patient records documentation system
  2. Integrate patient records system with the existing DHIS2/SmartCare Engagement of Support System Actors: The following strategies shall be used
  • Training of frontline healthworkers including Clinical Officers, Nurses and CHA/CHWs
  • Audit and feedback
  • Mentorship and facilitation with mid- and senior-level management within ministry of health (MoH) Zambia. Engagement of Synthesis \& Translation System Actors: The following strategies shall be deployed
  • Evidence-based messaging of health effects of NCDs for patients
  • Evidence-based messaging on the adverse effects of NCDs on outcomes for health care workers. Aim 2: Pilot the Adapted WHO-PEN Plus in two (2) selected First-Level Hospitals in both the Zambian peri-urban and rural primary care settings in the first funding phase then mirror this to two (2) more first level hospitals of the same nature in the next funding cycle.
  • Operationalising the Clinic model in the hospitals We will select implementation strategies to act at different levels of the Zambian healthcare system to overcome barriers to NCD integration. During the pilot, we will explore facilitators and barriers to the implementation of the WHO PEN-PLUS. The intervention will be fully task-shifted to mid-levels cadres, Clinical Officers and nurses, for implementation and fully integrated into the existing primary health care system in the target districts and facilities.
  • Establishment of PEN-Plus Training Centres The Clinics facilities shall be refurbished to include space for training and similar models shall be advocated in other hospitals which shall select the cadres for training. This shall be in preparation for national scaleup. Aim 3: Development of PEN-Plus Policies National Operational Plan In collaboration with the Ministry of Health and WHO Country Office, the processes for the development of the PEN-Plus national operation plan shall be evoked. This work will include assessing gaps in relevant clinical guidelines, formularies, clinical forms, regulations around scope of practice for mid-level providers such as nurses and Clinical Officers, and adaptation of training materials for national use in support of the Ministry of Health. The PEN-Plus national scale up will involve laying the foundation for national scale-up through a clear governance structure led by the MoH. The evolution of PEN-Plus planning shall benefit from MOH leadership and a wide variety of stakeholders including interdisciplinary MOH collaborators across several directorates and programs, implementing partners, academic institutions, civil society, wide-ranging clinical specialists, central hospitals, and funders. Specific objectives For Aim 1:
  • To strengthen management of severe and complex non-communicable diseases through task-shifting and task-sharing to most accessible health care workers For Aim 2:
  • To improve diagnostic capacities (skills and tools) for NCDs at first-level health facilities.
  • To enhance capacities of staff at a first-level hospital through availability of treatment protocols for standardization of treatment of severe and complex NCDs. For Aim 3:
  • To strengthen capacities for patient-centred services to improve adherence to NCDs treatment.
Being tested
Supportive treatment
Medical subject headings
Heart Diseases, Anemia, Sickle Cell, Hypertension, Diabetes Mellitus, Heart Failure, Heart Defects, Congenital, Rheumatic Heart Disease, Epilepsy

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • Supportive treatmentCombination product

    Also called insuline, hydroxyurea, Setting up of clinics, Setting up of training centres

    Buffering of drugs and or equipment to the MOH to ensure that HCWs are able to manage the patients that attend the NCD clinics set up within the first level hospitals.

Study groups in NCT07753681
Study groupRoleWhat they receive
Lusaka - Matero FLHCommunity accessing care from first level hospitals in different parts of Zambia
Receives: Combination Product: Supportive treatment
Central - Mwachisompola FLHCommunity accessing care from first level hospitals in different parts of Zambia
Receives: Combination Product: Supportive treatment
Central - Kapiri Mposhi DHCommunity accessing care from first level hospitals in different parts of Zambia
Receives: Combination Product: Supportive treatment
Chifubu first level hospitalNCD patients presenting with severe NCDs at the hospital
Chipata district hospitalNCD patients presenting with severe NCDs at the hospital

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Percentage increase in patients with severe and complex NCDs diagnosed and managed at first-level hospitals according to WHO PEN-Plus guidelines.

    Increased access to quality NCD services at primary care level.

    Measured: 6 years

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted7 Aug 2026
  2. Study start8 Aug 2022
  3. Primary completion30 Sep 2027 (estimated)
  4. Study completion30 Sep 2027 (estimated)

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Observational
Observational model
Case only
Time perspective
Prospective
Enrolment
2,084 participants (estimated)
Target duration
1 Month
IDs, dates and publications
ClinicalTrials.gov ID
NCT07753681
Sponsor's protocol ID
3032-2022 PEN-Plus
Other IDs
01, 01
Acronym
PEN Plus
Status last verified
Aug 2026
First submitted
3 Apr 2025
Last updated
7 Aug 2026
Results posted
No
Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
Individual data sharing
Yes: The de-identified patient data may be shared with other researchers or the purposes of analysis. Where personal identifiers are shared, there is a data protection and sharing contract that has been put in place.

Publications

  • https://journals.plos.org/globalpublichealth/article?id=10.1371/journal.pgph.0004398

  • https://static1.squarespace.com/static/64dbb4573bca0b2b659240f5/t/68a89cc8f373370f961131ad/1755880648256/Zambia+PEN-Plus+National+Operational+Plan_11Jul2025_FINAL.pdf

Questions about this trial

What is this clinical trial studying?

An observational study of Cardiac Diseases and Sickle Cell Disease, run by Centre for Infectious Disease Research in Zambia at 1 site in Zambia.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 1 inclusion and 1 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: looking for participants now, as of the sponsor's last update on 7 Aug 2026. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 1 site in Zambia. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

This study is still under way. Results are not available in the source record yet.

How can a doctor refer a patient or contact the research team?

Contact Bupe Sichalwe, ADULT EDUCATION (977401513 ext. +260, bupe.sichalwe@cidrz.org), or a site near the patient. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Percentage increase in patients with severe and complex NCDs diagnosed and managed at first-level hospitals according to WHO PEN-Plus guidelines. (time frame: 6 years). It is what the study was designed to measure, not a finding.

Where can I read the original study information?

On the ClinicalTrials.gov record for NCT07753681, which also lists 2 linked publications.

Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 7 Aug 2026.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in